Information Provided By:
Fly News Breaks for February 10, 2020
Feb 10, 2020 | 10:11 EDT
Wedbush analyst Laura Chico views the weakness today in shares of Biohaven Pharmaceutical after troriluzole failed to meet its primary endpoint in a Phase 3 trial for the treatment of generalized anxiety disorder as a buying opportunity. The analyst says that while the miss is unfortunate, troriluzole is not part of her estimates at this point. The analyst remains focused on the upcoming rimegepant prevention data and the acute treatment FDA action date in late February. Chico sees a favorable risk/reward into the upcoming rimegepant catalysts and keeps an Outperform rating on Biohaven Pharmaceutical with a $75 price target.
News For BHVN From the Last 2 Days
There are no results for your query BHVN